Skip to content

Search

Antisense Transcription in Loci Associated to Hereditary Neurodegenerative Diseases

Evidence for the existence of additional regulatory mechanisms of the expression of neurodegenerative disease-causing genes by antisense long noncoding RNAs

Cellular and molecular changes to cortical neurons following low intensity repetitive magnetic stimulation at different frequencies

A systematic comparison of the cellular and molecular changes in neurons in vitro induced by low intensity magnetic stimulation at different frequencies.

Technical Advance: Transcription factor, promoter, and enhancer utilization in human myeloid cells

The generation of myeloid cells from their progenitors is regulated at the level of transcription by combinatorial control of key transcription factors...

Telomerase reverse transcriptase regulates microRNAs.

This study reports that telomerase reverse transcriptase extensively affects the expression levels of mature microRNAs.

TagDust2: A generic method to extract reads from sequencing data.

Arguably the most basic step in the analysis of next generation sequencing data (NGS) involves the extraction of mappable reads from the raw reads...

Gateways to the FANTOM5 promoter level mammalian expression atlas

The FANTOM5 project investigates transcription initiation activities in more than 1,000 human and mouse primary cells, cell lines and tissues using CAGE.

Linking FANTOM5 CAGE peaks to annotations with CAGEscan

Here, we present the production and quality control of CAGEscan libraries from 56 FANTOM5 RNA sources

Data Descriptor: Monitoring transcription initiation activities in rat and dog

The promoter landscape of several non-human model organisms is far from complete

An integrated expression atlas of miRNAs and their promoters in human and mouse

We provided a broad atlas of miRNA expression and promoters in primary mammalian cells, establishing a foundation for detailed analysis of miRNA.

Temporally restricted activation of IFNβ signaling determines response to immune checkpoint therapy

The biological determinants of the response to immune checkpoint blockade (ICB) in cancer remain incompletely understood. Little is known about dynamic biological events that underpin therapeutic efficacy due to the inability to frequently sample tumours in patients.